-
New results from SELECT show reduction in progression to diabetes
Semaglutide is best known as a weight loss drug, yet SELECT was not a weight loss study. It was a secondary cardioprevention trial, explained Donna H. Ryan, MD, one of the experts presenting results from SELECT.
-
SURMOUNT-OSA findings demonstrate benefit of tirzepatide in treatment of obesity-related OSA
The drug has been shown to improve sleep apnea severity and related cardiometabolic issues in people with moderate-to-severe obstructive sleep apnea, reported investigators including Atul Malhotra, MD, and Louis J. Aronne, MD, FACP, DABOM.
-
INHALE-3 investigators detail benefits of inhaled insulin for type 1 diabetes
Study Chair Irl B. Hirsch, MD, reported that inhaled insulin may be good for patients who are engaged in their diabetes self-management and want to reduce hyperglycemia even further, and for patients who want an alternative to a pump.
-
Meet poster presenters and explore the Exhibit Hall on Sunday
Poster presenters will be available for discussion at their poster boards during Sunday’s General Poster Session. Industry representatives also will be in the Exhibit Hall from 10:00 a.m. – 4:00 p.m.
-
Diabetes symposium will elucidate the key role of the central nervous system in metabolic control
“The role of the central nervous system (CNS) in metabolic regulation has important implications for normal physiology and for disease, and this symposium was constructed to highlight how these may contribute to diabetes,” said Diabetes® Editor in Chief David A. D’Alessio, MD.
-
Session to outline nutrition interventions that work
Gamification, prescriptions for fresh produce, and nutrition education have proven successful components to diabetes prevention and treatment. Panelists including Grace E. Shearrer, PhD, will explain how these concepts have been put into action in the real world.
-
Panel will address issues and challenges around CGM use in pregnancy
A Sunday symposium will explore evolving evidence for CGM use in pregnancy. Sarit Polsky, MD, MPH, one of the expert panelists, will compare time in range versus conventional fasting and postprandial targets in pregnancy.
-
Symposium will examine mechanisms of GLP-1/GIP-mediated metabolic regulation and side effects of GLP-1/GIP-based therapies
Dual agonists of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have taken center stage in the treatment of obesity and type 2 diabetes. Experts, including Timo D. Müller, PhD, will explore GLP-1/GIP-mediated energy metabolism.
-
Researchers highlight complicated dynamics of SARS-CoV-2 and type 1 diabetes
Carmella Evans-Molina, MD, PhD, and Peter K. Jackson, PhD, presented differing views on whether COVID-19 infection can cause type 1 diabetes in a debate on the opening day of the 84th Scientific Sessions in Orlando.
-
Experts will discuss evolving paradigms and evidence on kidney disease in diabetes
Diabetes is the leading cause of kidney disease and kidney failure. Panelists including Andrew Advani, BSc, MBChB(Hons), PhD, FRCP(UK), FRCP(Edin), FASN, will explore shifting disease management strategies.